| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-102 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于变更公司董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 奕瑞电子科技集团股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书邱敏女士的辞职报告，邱敏女士因个人原因申请辞去公司董事会秘 书职务，辞职后不再担任公司任何职务。根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《奕瑞电子科技集团股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，邱敏女士的辞职报告自送达公司董事会之日起生效。 邱敏女士已按照公司离职管理制度做好了交接工作，其辞任不会对公司正常 经营活动产生不利影响。 一、公司董事会秘书离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职 | | | 原定任期 | | 离任 | 是否继续在上 | 具体职 | 是否存在未 | | -- ...

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-104 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于部分募集资金投资项目新增实施主体和实施地 点、调整内部结构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 奕瑞电子科技集团股份有限公司（以下简称"公司"或"奕瑞科技"）于 2025 年 12 月 17 日召开第三届董事会第二十二次会议，审议通过了《关于部分募集资 金投资项目新增实施主体和实施地点、调整内部结构的议案》，同意公司可转债 募集资金投资项目（以下简称"募投项目"）"数字化 X 线探测器关键技术研 发和综合创新基地建设项目"增加实施主体及实施地点，同意公司在不改变募集 资金投向、不改变募投项目总投资金额、不影响募投项目正常实施的情况下对"数 字化 X 线探测器关键技术研发和综合创新基地建设项目"内部结构进行调整， 并授权公司董事长或董事长之授权人士办理相关事项。保荐机构中国国际金融股 份有限公 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-105 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于使用自有资金支付募投项目所需资金并以募集 资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 12 月 17 日召开了第三届董事会审计委员会 2025 年第七次会议、第三届董事会第二十二 次会议，审议通过了《关于使用自有资金支付募投项目所需资金并以募集资金等 额置换的议案》，同意公司在募集资金投资项目（以下简称"募投项目"）实施期 间，根据实际情况先行使用自有资金支付募投项目所需资金，在履行内部相关审 批程序后以募集资金等额置换，该部分等额置换资金视同募投项目已使用资金。 保荐机构中国国际金融股份有限公司对本事项出具了明确的核查意见，现将具体 情况公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-100 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 第三届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2025 年 12 月 17 日，奕瑞电子科技集团股份有限公司（以下简称"公司"或"奕 瑞科技"）以现场及通讯方式召开了第三届董事会第二十二次会议（以下简称"本 次会议"），会议通知已于 2025 年 12 月 15 日以电子邮件形式发出。本次会议由 董事长 Tieer Gu 先生主持，会议应出席董事 9 人，实际出席并表决的董事 9 人。 本次会议的召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 等相关法律、法规以及《奕瑞电子科技集团股份有限公司章程》（以下简称"《公 司章程》"）的有关规定。 二、董事会会议审议情况 （一）审议通过了《关于以集中竞价交易方式回购公司股份方案的议案 ...

Group 1 - The core point of the article is that Yirui Technology (SH 688301) announced a board meeting on December 17, 2025, to discuss the proposal for changing the company secretary [1] - For the fiscal year 2024, Yirui Technology's revenue composition is as follows: digital X-ray detectors account for 93.53%, while other businesses make up 6.47% [1] - As of the report, Yirui Technology has a market capitalization of 20.6 billion yuan [1]

Group 1 - The core point of the news is the resignation of the company secretary, Qiu Min, due to personal reasons, and the appointment of Bian Ren as the new company secretary to ensure the smooth operation of the board and information disclosure [1] - The revenue composition for Yirui Technology in 2024 is projected to be 93.53% from digital X-ray detectors and 6.47% from other businesses [1] - The current market capitalization of Yirui Technology is 20.6 billion yuan [2]

作为辐射探测领域的核心转换材料，钆镓铝基稀土石榴石结构闪烁陶瓷（GAGG）正迎来产业化突破。 国内数字X线影像系统核心部件领军企业奕瑞科技（688301.SH）在继成功量产医疗CT用GOS陶瓷后， 再次取得关键进展，正式宣布GAGG稀土透明陶瓷投入规模化生产，并建成年产吨级的立方晶系GAGG 产线。 图示 GAGG稀土透明陶瓷 此次量产落地，标志着奕瑞已掌握从软X射线到高能γ射线的全能谱探测材料量产能力，将为下游探测 与成像装备的技术升级与应用拓展提供坚实的核心材料支撑。业内认为，奕瑞坚持不懈的技术与产品革 新，未来有望持续受益于工业检测、医疗影像等领域的需求增长，进一步加强其在全球辐射探测核心部 件市场的地位。 GAGG稀土透明陶瓷的量产，源于奕瑞研发人员"寓精于料，料要成材，材要成器，器要好用"的质朴开 发理念，公司贯通了从荧光粉合成、陶瓷制备、像素阵列加工到探测器模组封装的全栈式自主技术链， 通过能带工程、缺陷工程、价态工程及微观结构优化，协同实现了高闪烁性能与优异透过率的统一。公 司采用纳米技术制备高活性粉体、超高温与高压"炼丹炉"炼制零气孔多晶陶瓷，规避了贵金属坩埚投入 大、能耗高、组分不均等传统工 ...

Investment Rating - The report maintains an "Outperform" rating for the machinery equipment industry [5][12]. Core Views - The focus on humanoid robots and AI infrastructure is expected to drive significant growth in the industry, with the U.S. government under Trump prioritizing the development of the robotics sector [2][19]. - TikTok plans to invest $38 billion in building a data center in Brazil, indicating a strong commitment to AI infrastructure [20]. - Jerry Holdings has secured contracts exceeding $100 million for generator sets, highlighting its competitive advantage in the data center power supply sector [21]. Humanoid Robots - Humanoid robots are seen as a crucial carrier for AI, with ongoing advancements expected to continue. The report suggests focusing on companies with strong positions in the supply chain, particularly those linked to Tesla [2][9]. - Key companies to watch include: - Core suppliers: Feirongda, Longxi Co., Weiman Sealing, Hengli Hydraulic, Huichuan Technology, Green Harmony, Lens Technology, and Wuzhou New Spring [2]. - Incremental opportunities: Weiman Sealing, Longxi Co., Feirongda, Weike Technology, and Hanwei Technology [2][9]. AI Infrastructure - AI computing power is identified as a high-growth investment theme, with a focus on the energy supply chain for AI data centers. Gas turbines are expected to benefit significantly from the demand for data center power [3][9]. - Key companies in the gas turbine supply chain include: - Gas turbine hot-end blades: Yingliu Co., Wanze Co. - Gas turbine generator sets: Jerry Holdings. - Other components: Haomai Technology, Liande Co., and supporting heat recovery steam generators [3][9]. Key Company Earnings Forecast and Investment Ratings - The report provides earnings forecasts and investment ratings for several companies, all rated as "Outperform": - Green Harmony: 2024 EPS of 0.33, PE of 474 [12][29]. - Mingzhi Electric: 2024 EPS of 0.19, PE of 370 [12][29]. - Huichuan Technology: 2024 EPS of 1.60, PE of 46 [12][29]. - Hengli Hydraulic: 2024 EPS of 1.87, PE of 60 [12][29]. - Longxi Co.: 2024 EPS of 0.31, PE of 91 [12][29]. - Yingliu Co.: 2024 EPS of 0.42, PE of 97 [12][29].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index rose by 0.90%, with notable increases in constituent stocks such as Green Harmony (+7.08%), Yirui Technology (+4.23%), and others [1] - The Sci-Tech 100 ETF (588800) experienced a trading volume of 2.10 billion yuan with a turnover rate of 8.34%, indicating strong market interest [1] - The Semiconductor Materials and Equipment Theme Index on the Sci-Tech Board increased by 1.55%, with key stocks like Zhongke Feimeng (+4.39%) and Chip Source Micro (+4.08%) showing significant gains [1] Group 2 - China Galaxy Securities highlighted the long-term growth potential of analog chips in the context of smart and electric trends, emphasizing the importance of companies with technological advantages in AI and automotive sectors [2] - The Sci-Tech 100 ETF (588800) is the first and only mid-cap index tracking high-growth tech companies, focusing on semiconductor, pharmaceutical, and new energy sectors [2] - The Semiconductor ETF (588170) tracks the Semiconductor Materials and Equipment Theme Index, which includes companies in semiconductor equipment (61%) and materials (23%), benefiting from domestic substitution and AI-driven demand [2]

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]